1 hr. ago
On August 11, Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter earnings call to deliver two headlines at once. CEO Claire Mazumdar announced she will step into a Vice Chair and Strategic Adviser role at the start of next year, handing the top job to President and Chief Operating Officer Ryan Cohlhepp. That handoff arrives just as the company points to fresh survival data for ficerafusp alfa, its lead drug candidate for frontline recurrent or metastatic HPV-negative head and neck cancer, and pushes its pivotal trial toward a critical readout.
At May's ASCO meeting, Bicara presented three-year follow-up data spanning roughly 90 patients across three dose cohorts, the longest follow-up reported for any investigational agent in HPV-negative head and neck cancer. At the 1,500 milligram weekly pivotal dose, about one in three patients was still alive at three years, roughly double the survival rate seen in retrospective **** yses of standard-of-care pembrolizumab in this population. Management ties that benefit to the drug's TGF-beta inhibition, which it says drives tumor penetration and immune cell infiltration rather than blocking a single pathway. Overall survival nearly doubled against the standard of care while the safety profile stayed consistent, the company said.
Execution on the pivotal Phase III FORTIFI-HN01 study has kept pace. Bicara says it is on track for substantial enrollment by the end of 2026, with more than 200 sites now active, positioning the trial for a mid-2027 interim readout that could open the door to accelerated approval. The company also launched FORTIFI-FLEX, a study of an every-three-week maintenance dose built on encouraging results from an exploratory every-two-week cohort shown earlier this year, with data targeted for the time of any U.S. approval decision. Beyond the core indication, Bicara points to early proof of concept in cutaneous squamous cell carcinoma and **** canal cancer, backed by roughly $497 million in cash that management says funds operations through the first half of 2029.
The leadership overhaul goes well beyond the CEO chair. Jenn Larson took over as Chief Financial Officer the day after the call, succeeding Ivan Hyep, who had a hand in raising over $800 million for the company since its early days. Two more transitions take effect in January: Chief Development Officer Tanya Green moves into the Chief Operating Officer seat, and Chief Corporate Affairs Officer Jenna Cohen becomes Chief Business Officer. A new Chief Legal Officer and two new board members are joining as well, a lot of change concentrated in a single quarter right as the company approaches its most consequential trial milestone.
#bicara #three #survival #cancer
At May's ASCO meeting, Bicara presented three-year follow-up data spanning roughly 90 patients across three dose cohorts, the longest follow-up reported for any investigational agent in HPV-negative head and neck cancer. At the 1,500 milligram weekly pivotal dose, about one in three patients was still alive at three years, roughly double the survival rate seen in retrospective **** yses of standard-of-care pembrolizumab in this population. Management ties that benefit to the drug's TGF-beta inhibition, which it says drives tumor penetration and immune cell infiltration rather than blocking a single pathway. Overall survival nearly doubled against the standard of care while the safety profile stayed consistent, the company said.
Execution on the pivotal Phase III FORTIFI-HN01 study has kept pace. Bicara says it is on track for substantial enrollment by the end of 2026, with more than 200 sites now active, positioning the trial for a mid-2027 interim readout that could open the door to accelerated approval. The company also launched FORTIFI-FLEX, a study of an every-three-week maintenance dose built on encouraging results from an exploratory every-two-week cohort shown earlier this year, with data targeted for the time of any U.S. approval decision. Beyond the core indication, Bicara points to early proof of concept in cutaneous squamous cell carcinoma and **** canal cancer, backed by roughly $497 million in cash that management says funds operations through the first half of 2029.
The leadership overhaul goes well beyond the CEO chair. Jenn Larson took over as Chief Financial Officer the day after the call, succeeding Ivan Hyep, who had a hand in raising over $800 million for the company since its early days. Two more transitions take effect in January: Chief Development Officer Tanya Green moves into the Chief Operating Officer seat, and Chief Corporate Affairs Officer Jenna Cohen becomes Chief Business Officer. A new Chief Legal Officer and two new board members are joining as well, a lot of change concentrated in a single quarter right as the company approaches its most consequential trial milestone.
#bicara #three #survival #cancer
2 hours ago
Police in Australia have apologized after the family of an 18-year-old hiker missing in dense bushland for eight days was mistakenly informed that she had been found alive.
In fact, Lily Hooper's body was found and now an investigation is underway to determine how she went missing and how her family received the wrong news.
Hooper left Oakdale, New South Wales (NSW), on August 12 to go for a solo hike in the Nattai National Park, but was reported missing after she didn't return home that night, according to a statement from NSW Police.
A multi-agency search operation was launched and lasted until early Thursday, when the news was conveyed that she'd been found.
Her family, believing she was still alive, were seen celebrating at the search site. The state premier Chris Minns even announced her survival during a live broadcast of a senate committee hearing.
#missing
In fact, Lily Hooper's body was found and now an investigation is underway to determine how she went missing and how her family received the wrong news.
Hooper left Oakdale, New South Wales (NSW), on August 12 to go for a solo hike in the Nattai National Park, but was reported missing after she didn't return home that night, according to a statement from NSW Police.
A multi-agency search operation was launched and lasted until early Thursday, when the news was conveyed that she'd been found.
Her family, believing she was still alive, were seen celebrating at the search site. The state premier Chris Minns even announced her survival during a live broadcast of a senate committee hearing.
#missing
5 hours ago
On August 11, Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter earnings call to deliver two headlines at once. CEO Claire Mazumdar announced she will step into a Vice Chair and Strategic Adviser role at the start of next year, handing the top job to President and Chief Operating Officer Ryan Cohlhepp. That handoff arrives just as the company points to fresh survival data for ficerafusp alfa, its lead drug candidate for frontline recurrent or metastatic HPV-negative head and neck cancer, and pushes its pivotal trial toward a critical readout.
At May's ASCO meeting, Bicara presented three-year follow-up data spanning roughly 90 patients across three dose cohorts, the longest follow-up reported for any investigational agent in HPV-negative head and neck cancer. At the 1,500 milligram weekly pivotal dose, about one in three patients was still alive at three years, roughly double the survival rate seen in retrospective ****** yses of standard-of-care pembrolizumab in this population. Management ties that benefit to the drug's TGF-beta inhibition, which it says drives tumor penetration and immune cell infiltration rather than blocking a single pathway. Overall survival nearly doubled against the standard of care while the safety profile stayed consistent, the company said.
Execution on the pivotal Phase III FORTIFI-HN01 study has kept pace. Bicara says it is on track for substantial enrollment by the end of 2026, with more than 200 sites now active, positioning the trial for a mid-2027 interim readout that could open the door to accelerated approval. The company also launched FORTIFI-FLEX, a study of an every-three-week maintenance dose built on encouraging results from an exploratory every-two-week cohort shown earlier this year, with data targeted for the time of any U.S. approval decision. Beyond the core indication, Bicara points to early proof of concept in cutaneous squamous cell carcinoma and ****** canal cancer, backed by roughly $497 million in cash that management says funds operations through the first half of 2029.
The leadership overhaul goes well beyond the CEO chair. Jenn Larson took over as Chief Financial Officer the day after the call, succeeding Ivan Hyep, who had a hand in raising over $800 million for the company since its early days. Two more transitions take effect in January: Chief Development Officer Tanya Green moves into the Chief Operating Officer seat, and Chief Corporate Affairs Officer Jenna Cohen becomes Chief Business Officer. A new Chief Legal Officer and two new board members are joining as well, a lot of change concentrated in a single quarter right as the company approaches its most consequential trial milestone.
#three
At May's ASCO meeting, Bicara presented three-year follow-up data spanning roughly 90 patients across three dose cohorts, the longest follow-up reported for any investigational agent in HPV-negative head and neck cancer. At the 1,500 milligram weekly pivotal dose, about one in three patients was still alive at three years, roughly double the survival rate seen in retrospective ****** yses of standard-of-care pembrolizumab in this population. Management ties that benefit to the drug's TGF-beta inhibition, which it says drives tumor penetration and immune cell infiltration rather than blocking a single pathway. Overall survival nearly doubled against the standard of care while the safety profile stayed consistent, the company said.
Execution on the pivotal Phase III FORTIFI-HN01 study has kept pace. Bicara says it is on track for substantial enrollment by the end of 2026, with more than 200 sites now active, positioning the trial for a mid-2027 interim readout that could open the door to accelerated approval. The company also launched FORTIFI-FLEX, a study of an every-three-week maintenance dose built on encouraging results from an exploratory every-two-week cohort shown earlier this year, with data targeted for the time of any U.S. approval decision. Beyond the core indication, Bicara points to early proof of concept in cutaneous squamous cell carcinoma and ****** canal cancer, backed by roughly $497 million in cash that management says funds operations through the first half of 2029.
The leadership overhaul goes well beyond the CEO chair. Jenn Larson took over as Chief Financial Officer the day after the call, succeeding Ivan Hyep, who had a hand in raising over $800 million for the company since its early days. Two more transitions take effect in January: Chief Development Officer Tanya Green moves into the Chief Operating Officer seat, and Chief Corporate Affairs Officer Jenna Cohen becomes Chief Business Officer. A new Chief Legal Officer and two new board members are joining as well, a lot of change concentrated in a single quarter right as the company approaches its most consequential trial milestone.
#three
6 hours ago
Hull City owner Acun Ilicali has criticised pundits Joe Cole and Carlton Cole after they mocked his side's chances of Premier League survival on a podcast.
Speaking on The Dressing Room podcast, former England and Chelsea midfielder Joe Cole said he had turned down the chance to be a pundit for their opening match - adding he would be "stunned if they stayed up".
He joked: "They've come here through the back door. They've slipped in."
Hull achieved promotion to the Premier League with a last-minute win over Middlesbrough in the play-off final at Wembley in May.
This season will be Hull's first in the Premier League since 2017. They only survived relegation from the Championship to League One on goal difference in 2025.
#league #podcast #acun
Speaking on The Dressing Room podcast, former England and Chelsea midfielder Joe Cole said he had turned down the chance to be a pundit for their opening match - adding he would be "stunned if they stayed up".
He joked: "They've come here through the back door. They've slipped in."
Hull achieved promotion to the Premier League with a last-minute win over Middlesbrough in the play-off final at Wembley in May.
This season will be Hull's first in the Premier League since 2017. They only survived relegation from the Championship to League One on goal difference in 2025.
#league #podcast #acun
8 hours ago
LIV Golf is not guaranteed to exist once the 2027 season gets underway. After years of enormous contracts, high-profile defections and attempts to disrupt professional golf, the league is now fighting to secure fresh investment and facing serious questions about what comes next.
The 2026 season has arguably been the most turbulent in LIV's short history. Instability followed Brooks Koepka's decision at the end of 2025 to pursue a return to the PGA Tour, while rumors intensified during The Masters that Saudi Arabia's Public Investment Fund could walk away.
New Orleans has since been postponed, doubts have emerged over the Team Championship, and several players have reportedly indicated privately that they intend to leave after the season, regardless of whether new funding arrives.
LIV did not reach this position because of one decision. Several choices along the way arguably made survival much harder.
USA TODAY Sports via Reuters Connect
#decision #instability #tour
The 2026 season has arguably been the most turbulent in LIV's short history. Instability followed Brooks Koepka's decision at the end of 2025 to pursue a return to the PGA Tour, while rumors intensified during The Masters that Saudi Arabia's Public Investment Fund could walk away.
New Orleans has since been postponed, doubts have emerged over the Team Championship, and several players have reportedly indicated privately that they intend to leave after the season, regardless of whether new funding arrives.
LIV did not reach this position because of one decision. Several choices along the way arguably made survival much harder.
USA TODAY Sports via Reuters Connect
#decision #instability #tour
4 days ago
After plenty of speculation, Dancing With the Stars pro Witney Carson finally revealed that she is indeed pregnant with baby number three.
The 32-year-old first announced her pregnancy Monday morning on Good Morning America, sharing that she and her husband, Carson McAllister, are preparing to welcome another member to their brood.
Carson also spoke to PEOPLE, saying, "My family is growing. We're so blessed to keep growing our family." The professional dancer added, "I can't wait to become a family of five."
As any expectant mother knows, working full time during a pregnancy isn't always easy. Add in a physically demanding job, like dancing, and the struggle is real. Carson candidly opened up to PEOPLE about how she's handling it this time around. "I am just in pure survival mode, she said. "I am constantly trying to eat to keep nausea at bay. I'm trying to rest as much as I can. I think with two toddlers, it's very difficult to rest, but my husband has been an absolute champ, and he has allowed me to rest, and he's very much taking care of all of us."
Disney/Andrew Eccles
#family
The 32-year-old first announced her pregnancy Monday morning on Good Morning America, sharing that she and her husband, Carson McAllister, are preparing to welcome another member to their brood.
Carson also spoke to PEOPLE, saying, "My family is growing. We're so blessed to keep growing our family." The professional dancer added, "I can't wait to become a family of five."
As any expectant mother knows, working full time during a pregnancy isn't always easy. Add in a physically demanding job, like dancing, and the struggle is real. Carson candidly opened up to PEOPLE about how she's handling it this time around. "I am just in pure survival mode, she said. "I am constantly trying to eat to keep nausea at bay. I'm trying to rest as much as I can. I think with two toddlers, it's very difficult to rest, but my husband has been an absolute champ, and he has allowed me to rest, and he's very much taking care of all of us."
Disney/Andrew Eccles
#family
4 days ago
American actress and star of Heroes and Nashville, Hayden Panettiere has died at 36-no cause of death has been made available at this time.
Known for her TV roles as Claire Bennet on the series Heroes and Juliette Barnes on Nashville, and played Kirby Reed in the Scream franchise-Hayden Panettiere has died at the age of 36 on Sunday, August 16, 2026. ABC News was the first to report on the news, with which her family's representative provided a statement. Panettiere died in South Carolina, and the investigation into her death is still "ongoing"-according to her representative. Panettiere's father asked for privacy "as our family takes time to process this unimaginable loss."
"It is with profound sadness that we share the tragic passing of our beloved Hayden," her father, Alan Lee "Skip" Panettiere, said in a statement to ABC News on Sunday. "She was an incredible light and a force of nature who brought immeasurable love and joy to all who knew her-and to the millions who watched her onscreen." While many know Hayden Panettiere for her roles in Heroes and Nashville, she was also remembered in other films: A Bug's Life, Remember the ****** ans, I Love You, Beth Cooper, Raising Helen, Ice Princess, Scream 4, and Scream 6.
In the video game world, Hayden Panettiere is widely known to voice Kairi in Kingdom Hearts, Kingdom Hearts II, and Birth by Sleep. She also voiced Xion in Kingdom Hearts 3D: Dream Drop Distance. This is especially tragic, as Kingdom Hearts IV news was just announced at D23 2026. One of the most surprising VA roles for Panettiere in a video game was Supermassive Games' Until Dawn, where she voiced and had her likeness used for the character Samantha "Sam" Giddings. Her performance enhance and push the interactive drama, survival-horror genre across the video games industry.
Panettiere has been quite honest about her struggles from childhood stardom, going into adulthood. She released a memoir this past May called This Is Me: A Reckoning. In the memoir, she shared "a rare and intimate glimpse into her life behind closed doors, opening up about postpartum depression, addiction and recovery, trauma, domestic abuse, and loss," according to a synopsis for her book. In recent interviews and in the memoir, she spoke on her difficulties following her role on Nashville.
#nashville #died #roles
Known for her TV roles as Claire Bennet on the series Heroes and Juliette Barnes on Nashville, and played Kirby Reed in the Scream franchise-Hayden Panettiere has died at the age of 36 on Sunday, August 16, 2026. ABC News was the first to report on the news, with which her family's representative provided a statement. Panettiere died in South Carolina, and the investigation into her death is still "ongoing"-according to her representative. Panettiere's father asked for privacy "as our family takes time to process this unimaginable loss."
"It is with profound sadness that we share the tragic passing of our beloved Hayden," her father, Alan Lee "Skip" Panettiere, said in a statement to ABC News on Sunday. "She was an incredible light and a force of nature who brought immeasurable love and joy to all who knew her-and to the millions who watched her onscreen." While many know Hayden Panettiere for her roles in Heroes and Nashville, she was also remembered in other films: A Bug's Life, Remember the ****** ans, I Love You, Beth Cooper, Raising Helen, Ice Princess, Scream 4, and Scream 6.
In the video game world, Hayden Panettiere is widely known to voice Kairi in Kingdom Hearts, Kingdom Hearts II, and Birth by Sleep. She also voiced Xion in Kingdom Hearts 3D: Dream Drop Distance. This is especially tragic, as Kingdom Hearts IV news was just announced at D23 2026. One of the most surprising VA roles for Panettiere in a video game was Supermassive Games' Until Dawn, where she voiced and had her likeness used for the character Samantha "Sam" Giddings. Her performance enhance and push the interactive drama, survival-horror genre across the video games industry.
Panettiere has been quite honest about her struggles from childhood stardom, going into adulthood. She released a memoir this past May called This Is Me: A Reckoning. In the memoir, she shared "a rare and intimate glimpse into her life behind closed doors, opening up about postpartum depression, addiction and recovery, trauma, domestic abuse, and loss," according to a synopsis for her book. In recent interviews and in the memoir, she spoke on her difficulties following her role on Nashville.
#nashville #died #roles
5 days ago
When fans approach San Francisco 49ers backup tight end Jake Tonges these days, they typically ask about one of two things. At the top of the list has to be his game-winning touchdown grab in Seattle, which excused him from no-name status at the start of the 2025 season, to beat the eventual Super Bowl champion Seahawks. The other involves the fantasy football waiver wire. He giggled.
"Or some first touchdown betting line that they're telling me about," Tonges said.
Thursday, when the 49ers hosted the ****** ans, marked the first time he did not suit up for a preseason game. What once was the basis for his survival in the NFL became validation that he made it.
No one drafted Tonges. The Chicago Bears signed him as an undrafted free agent in 2022, along with more than a dozen others. For the next several Augusts, his sole focus was putting together good tape in the preseason so that he had something to show other teams in case he was, as an example, released with an injury settlement, the kind of niche NFL roster terminology fringe players learn quickly.
A campaign in which All-Pro tight end George Kittle missed six games in the regular season and another in the playoffs gave Tonges an opportunity to put the world of Silicon Valley tech and finance in the rearview. The Los Gatos native attended Cal as a walk-on who took BART into the city for an internship at Morgan Stanley.
#touchdown
"Or some first touchdown betting line that they're telling me about," Tonges said.
Thursday, when the 49ers hosted the ****** ans, marked the first time he did not suit up for a preseason game. What once was the basis for his survival in the NFL became validation that he made it.
No one drafted Tonges. The Chicago Bears signed him as an undrafted free agent in 2022, along with more than a dozen others. For the next several Augusts, his sole focus was putting together good tape in the preseason so that he had something to show other teams in case he was, as an example, released with an injury settlement, the kind of niche NFL roster terminology fringe players learn quickly.
A campaign in which All-Pro tight end George Kittle missed six games in the regular season and another in the playoffs gave Tonges an opportunity to put the world of Silicon Valley tech and finance in the rearview. The Los Gatos native attended Cal as a walk-on who took BART into the city for an internship at Morgan Stanley.
#touchdown
5 days ago
Former Wales captain Alun Wyn Jones is poised to return to the Ospreys as a director.
The 40-year-old is set to be announced as a board member by the Swansea-based club next week.
Jones made his Ospreys debut in 2005, a year after he broke through with Swansea RFC, and helped the club to three ****** les and an Anglo-Welsh Cup triumph.
The former lock is to return at a turbulent time as the club fights for survival under Welsh Rugby Union (WRU) plans to cut to three professional men's sides.
WRU-owned Cardiff and privately-backed Dragons are poised to get licences, which will effectively pit Ospreys against Llanelli-based Scarlets for a solitary spot in the west.
#swansea #poised
The 40-year-old is set to be announced as a board member by the Swansea-based club next week.
Jones made his Ospreys debut in 2005, a year after he broke through with Swansea RFC, and helped the club to three ****** les and an Anglo-Welsh Cup triumph.
The former lock is to return at a turbulent time as the club fights for survival under Welsh Rugby Union (WRU) plans to cut to three professional men's sides.
WRU-owned Cardiff and privately-backed Dragons are poised to get licences, which will effectively pit Ospreys against Llanelli-based Scarlets for a solitary spot in the west.
#swansea #poised
6 days ago
Leeds United are advancing in their pursuit of Nico Elvedi, with personal terms now reportedly agreed between the player and the Yorkshire club ahead of a potential move from Borussia Monchengladbach. As first reported by Florian Plettenberg, the proposed contract would run until 2029, with Leeds now expected to step up club-to-club negotiations.
This is shaping up to be another significant move in a summer that already carries real weight at Elland Road. Leeds have approached this window with purpose after securing Premier League survival last season, finishing 14th, and there is a clear sense that Daniel Farke wants to push the squad beyond simply staying up. Recruitment has reflected that ambition, with Harry Wilson arriving on a free transfer, Tarik Muharemovic joining for £34m and James Trafford signing from Manchester City for a club-record £40m.
Elvedi looks like a natural fit for where Leeds are heading. The 29-year-old brings experience, reliability and a level of tactical understanding that matters when a side is trying to become more stable in the Premier League. Borussia Monchengladbach are believed to be open to a sale if the conditions are right, while the player is understood to be keen on the opportunity to test himself in England.
From Leeds' perspective, the timing also makes sense. Defensive reinforcement has become a pressing priority after Pascal Struijk's departure to Brighton, especially with Farke having leaned into a back-three system during the run-in last season. Elvedi has the profile to suit that shape, given his reading of the game, composure in possession and comfort operating in an organised defensive unit.
There is also a valuable personal element to this pursuit. Farke knows Elvedi well from their time together in Germany, and that familiarity often helps move a deal from interest to genuine conviction. Managers do not push this hard unless they feel a player can improve the floor and ceiling of the side.
#leeds #club #borussia
This is shaping up to be another significant move in a summer that already carries real weight at Elland Road. Leeds have approached this window with purpose after securing Premier League survival last season, finishing 14th, and there is a clear sense that Daniel Farke wants to push the squad beyond simply staying up. Recruitment has reflected that ambition, with Harry Wilson arriving on a free transfer, Tarik Muharemovic joining for £34m and James Trafford signing from Manchester City for a club-record £40m.
Elvedi looks like a natural fit for where Leeds are heading. The 29-year-old brings experience, reliability and a level of tactical understanding that matters when a side is trying to become more stable in the Premier League. Borussia Monchengladbach are believed to be open to a sale if the conditions are right, while the player is understood to be keen on the opportunity to test himself in England.
From Leeds' perspective, the timing also makes sense. Defensive reinforcement has become a pressing priority after Pascal Struijk's departure to Brighton, especially with Farke having leaned into a back-three system during the run-in last season. Elvedi has the profile to suit that shape, given his reading of the game, composure in possession and comfort operating in an organised defensive unit.
There is also a valuable personal element to this pursuit. Farke knows Elvedi well from their time together in Germany, and that familiarity often helps move a deal from interest to genuine conviction. Managers do not push this hard unless they feel a player can improve the floor and ceiling of the side.
#leeds #club #borussia
9 days ago
It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate (FXN) basis year-over-year to $2.63, comfortably ahead of the $2.48 ***** yst consensus. Total revenue reached $15.38 billion, up 5% at constant exchange rates, driven primarily by sustained momentum in its Oncology and Rare Disease units. Management reconfirmed its full-year 2026 outlook of mid-to-high single-digit revenue growth and low double-digit Core EPS growth, expressing confidence in reaching its $80 billion total revenue target by 2030 despite near-term headwind shocks.
The quarter demonstrated strong commercial execution in core growth engines. Oncology revenue rose 16% to $7.33 billion, supported by strong demand for Tagrisso ($1.94 billion), Imfinzi ($1.85 billion), and Enhertu (+31%). Rare Disease contributed $4.9 billion, led by Ultomiris. These gains successfully offset severe pressures in the Cardiovascular, Renal & Metabolism (CVRM) segment, which declined 15% due to the loss of exclusivity (LOE) for Farxiga in the U.S. and ongoing Volume-Based Procurement (VBP) price cuts in China.
Meanwhile, pipeline updates presented a mixed picture. On July 27, AZN disclosed that a Phase 3 study evaluating Ultomiris in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) failed to hit its primary endpoint of event-free survival at week 26 versus placebo. Following the readout, H.C. Wainwright noted that the trial miss represents a "clear positive" for competitor Omeros (OMER), removing a major near-term competitive overhang on its drug Yartemlea and driving Omeros shares up 11% in morning trading.
AstraZeneca PLC (NASDAQ:AZN)'s core profitability remains elite, with core operating margins expanding to 34% in Q2 despite top-line headwinds from generic entry. High gross and net margins signal durable pricing power across its branded specialty portfolio. This strong profitability generates predictable cash flow to fund heavy R&D investments, commercial rollouts, and growing shareholder returns, including a 3-cent increase in the interim dividend to $1.06 per share, while buffering the company against pricing pressure.
The company's expansive late-stage pipeline and high volume of regulatory approvals underpin a multi-year growth trajectory. With 30 major regional approvals since late 2025 and more than 20 high-value trial readouts scheduled over the next 18 months, AZN possesses broad commercial optionality. Continued expansions in oncology (e.g., Enhertu and Imfinzi) and respiratory therapies (such as Breztri and Tezspire) provide direct revenue replacement for legacy products facing patent expiration.
#high #july
The quarter demonstrated strong commercial execution in core growth engines. Oncology revenue rose 16% to $7.33 billion, supported by strong demand for Tagrisso ($1.94 billion), Imfinzi ($1.85 billion), and Enhertu (+31%). Rare Disease contributed $4.9 billion, led by Ultomiris. These gains successfully offset severe pressures in the Cardiovascular, Renal & Metabolism (CVRM) segment, which declined 15% due to the loss of exclusivity (LOE) for Farxiga in the U.S. and ongoing Volume-Based Procurement (VBP) price cuts in China.
Meanwhile, pipeline updates presented a mixed picture. On July 27, AZN disclosed that a Phase 3 study evaluating Ultomiris in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) failed to hit its primary endpoint of event-free survival at week 26 versus placebo. Following the readout, H.C. Wainwright noted that the trial miss represents a "clear positive" for competitor Omeros (OMER), removing a major near-term competitive overhang on its drug Yartemlea and driving Omeros shares up 11% in morning trading.
AstraZeneca PLC (NASDAQ:AZN)'s core profitability remains elite, with core operating margins expanding to 34% in Q2 despite top-line headwinds from generic entry. High gross and net margins signal durable pricing power across its branded specialty portfolio. This strong profitability generates predictable cash flow to fund heavy R&D investments, commercial rollouts, and growing shareholder returns, including a 3-cent increase in the interim dividend to $1.06 per share, while buffering the company against pricing pressure.
The company's expansive late-stage pipeline and high volume of regulatory approvals underpin a multi-year growth trajectory. With 30 major regional approvals since late 2025 and more than 20 high-value trial readouts scheduled over the next 18 months, AZN possesses broad commercial optionality. Continued expansions in oncology (e.g., Enhertu and Imfinzi) and respiratory therapies (such as Breztri and Tezspire) provide direct revenue replacement for legacy products facing patent expiration.
#high #july
9 days ago
NEW DELHI: For a team with two ODI World Cup ***** les, West Indies have found themselves in an unfamiliar position again. The Caribbean side will not qualify automatically for the 2027 World Cup and must now negotiate the qualifying route to make the tournament in South Africa, Zimbabwe and Namibia.
It is the third straight World Cup cycle in which West Indies have been pushed into the qualifiers, underlining the difficult road the former champions now face.
The immediate challenge is the 2027 World Cup Qualifier in February, where West Indies will be joined by Ireland, four teams from the Cricket World Cup League 2 and four sides emerging from the Qualifier Playoff.
West Indies cannot secure one of the automatic qualification spots before the September 30 cut-off. They are currently 10th in the ODI rankings, and even two victories over India before the deadline would not be enough to move them into the required bracket.
That leaves the Qualifier as their route into the World Cup.
The tournament carries an important incentive: win it, and West Indies go straight into the second round of the 2027 World Cup.
But finishing between second and fourth would leave them with another hurdle. Those three teams will enter the first round of the World Cup, the Super Series, alongside another Qualifier team. Only the winner of that stage will progress to the second round.
In other words, West Indies have little room for error. Winning the Qualifier would provide the cleanest route, while anything less could mean another high-pressure battle for survival.
The Caribbean side already know what happens when the Qualifier campaign goes wrong.
West Indies failed to make the 2023 World Cup through direct qualification and subsequently finished fifth in the Super Six stage of the Qualifier. The result was historic for the wrong reasons: they missed a World Cup for the first time.
The consequences extended beyond that tournament. West Indies also failed to feature in the 2025 Champions Trophy, a competition they had not played since 2013.
Now, with another World Cup qualification campaign ahead, the former two-time champions face a familiar test. This time, the objective is simple: navigate the qualifiers successfully and ensure they are back on cricket's biggest ODI stage in 2027.
#champions #tournament
It is the third straight World Cup cycle in which West Indies have been pushed into the qualifiers, underlining the difficult road the former champions now face.
The immediate challenge is the 2027 World Cup Qualifier in February, where West Indies will be joined by Ireland, four teams from the Cricket World Cup League 2 and four sides emerging from the Qualifier Playoff.
West Indies cannot secure one of the automatic qualification spots before the September 30 cut-off. They are currently 10th in the ODI rankings, and even two victories over India before the deadline would not be enough to move them into the required bracket.
That leaves the Qualifier as their route into the World Cup.
The tournament carries an important incentive: win it, and West Indies go straight into the second round of the 2027 World Cup.
But finishing between second and fourth would leave them with another hurdle. Those three teams will enter the first round of the World Cup, the Super Series, alongside another Qualifier team. Only the winner of that stage will progress to the second round.
In other words, West Indies have little room for error. Winning the Qualifier would provide the cleanest route, while anything less could mean another high-pressure battle for survival.
The Caribbean side already know what happens when the Qualifier campaign goes wrong.
West Indies failed to make the 2023 World Cup through direct qualification and subsequently finished fifth in the Super Six stage of the Qualifier. The result was historic for the wrong reasons: they missed a World Cup for the first time.
The consequences extended beyond that tournament. West Indies also failed to feature in the 2025 Champions Trophy, a competition they had not played since 2013.
Now, with another World Cup qualification campaign ahead, the former two-time champions face a familiar test. This time, the objective is simple: navigate the qualifiers successfully and ensure they are back on cricket's biggest ODI stage in 2027.
#champions #tournament
9 days ago
Our **** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management is executing a planned leadership transition, elevating Ryan Cohlhepp to CEO to leverage his commercial oncology experience as the company nears potential launch.
The company's strategic focus remains on the pivotal Phase III FORTIFI-HN01 study for HPV-negative head and neck cancer, which is on track for substantial enrollment by year-end.
Three-year follow-up data presented at ASCO 2026 demonstrated that TGF-beta inhibition nearly doubled overall survival versus standard of care pembrolizumab in the pivotal dose cohort.
Management attributes clinical success to the mechanistic foundation of TGF-beta inhibition, which drives deeper tumor penetration and immune cell infiltration compared to standard EGFR-directed therapies.
#management #year
Management is executing a planned leadership transition, elevating Ryan Cohlhepp to CEO to leverage his commercial oncology experience as the company nears potential launch.
The company's strategic focus remains on the pivotal Phase III FORTIFI-HN01 study for HPV-negative head and neck cancer, which is on track for substantial enrollment by year-end.
Three-year follow-up data presented at ASCO 2026 demonstrated that TGF-beta inhibition nearly doubled overall survival versus standard of care pembrolizumab in the pivotal dose cohort.
Management attributes clinical success to the mechanistic foundation of TGF-beta inhibition, which drives deeper tumor penetration and immune cell infiltration compared to standard EGFR-directed therapies.
#management #year
10 days ago
The 2026/27 LALIGA season promises to be one of the most electrifying in recent memory. With multimillion-euro projects, marquee signings, and the return of historic clubs, the battle for the ****** le and survival will deliver high drama every matchday.
The Real Madrid dugout once again has the Portuguese coach as its leading figure. After strengthening with top-level names such as Cucurella and Diomande, Los Blancos are aiming to ****** the crown from FC Barcelona. However, in the Catalan capital there is no fear: the newly crowned champions boast a golden backbone made up of young world champions such as Lamine Yamal, Pedri, Gavi and Cubarsí. The battle at the top is expected to be fierce.
Atlético de Madrid do not want to be mere spectators in this clash of giants. Diego Pablo Simeone takes on the challenge with high-profile arrivals such as Alejandro Grimaldo, Morten Hjulmand and Kang-in Lee. The big question surrounding the Colchoneros lies in their consistency; they will have to show whether this new project has the substance needed to challenge the two superpowers of Spanish football for the ****** le on equal terms.
Behind the favorites, the race for European spots will be fierce. Sides such as Villarreal, Real Betis, Real Sociedad, Celta de Vigo and Getafe have geared up to deliver a fascinating campaign. Meanwhile, Athletic Club begin with the moral obligation to win back their place in continental competition, which will raise the bar in the upper-middle tier.
The other side of the coin features illustrious clubs hit by hardship. Historic sides such as Valencia CF and Sevilla FC are forced to deal with difficult transfer windows and marked institutional instability. For their fans, the immediate objective is survival: grow stronger through adversity, avoid trouble in the standings, and try to restore former glories through total commitment.
#historic #sides #battle #survival
The Real Madrid dugout once again has the Portuguese coach as its leading figure. After strengthening with top-level names such as Cucurella and Diomande, Los Blancos are aiming to ****** the crown from FC Barcelona. However, in the Catalan capital there is no fear: the newly crowned champions boast a golden backbone made up of young world champions such as Lamine Yamal, Pedri, Gavi and Cubarsí. The battle at the top is expected to be fierce.
Atlético de Madrid do not want to be mere spectators in this clash of giants. Diego Pablo Simeone takes on the challenge with high-profile arrivals such as Alejandro Grimaldo, Morten Hjulmand and Kang-in Lee. The big question surrounding the Colchoneros lies in their consistency; they will have to show whether this new project has the substance needed to challenge the two superpowers of Spanish football for the ****** le on equal terms.
Behind the favorites, the race for European spots will be fierce. Sides such as Villarreal, Real Betis, Real Sociedad, Celta de Vigo and Getafe have geared up to deliver a fascinating campaign. Meanwhile, Athletic Club begin with the moral obligation to win back their place in continental competition, which will raise the bar in the upper-middle tier.
The other side of the coin features illustrious clubs hit by hardship. Historic sides such as Valencia CF and Sevilla FC are forced to deal with difficult transfer windows and marked institutional instability. For their fans, the immediate objective is survival: grow stronger through adversity, avoid trouble in the standings, and try to restore former glories through total commitment.
#historic #sides #battle #survival
11 days ago
Brad Pitt has revealed that he once experienced suicidal thoughts over "family stuff".
The 62-year-old actor has revealed that for most of his life, he has been "a congenital optimist" and "never suicidal in any way".
However, there was "one little period" where he experienced suicidal ideation because he couldn't "see a way out" of that painful time.
"I've never been suicidal except for one little period. And in that one little period, I just thought - I just couldn't - just didn't see a way out," he candidly told Esquire. "The pain was so oppressive that - I wasn't going to act on this, but I could feel - I could feel the cold steel of the bullet in my head, and it felt like relief.
"And I thought, Oh, okay, now I understand - I understand suicide, in the sense that it's just relief. It's just looking for relief from the pain. But I also think we have incredible survival instincts. And for me, that immediately kicked in, but it was just..."
After a pause, the Fight Club actor added, "Yeah. Like, listen: This s**t ain't easy. And you're talking to a guy who won the lottery."
#little #relief #experienced #actor
The 62-year-old actor has revealed that for most of his life, he has been "a congenital optimist" and "never suicidal in any way".
However, there was "one little period" where he experienced suicidal ideation because he couldn't "see a way out" of that painful time.
"I've never been suicidal except for one little period. And in that one little period, I just thought - I just couldn't - just didn't see a way out," he candidly told Esquire. "The pain was so oppressive that - I wasn't going to act on this, but I could feel - I could feel the cold steel of the bullet in my head, and it felt like relief.
"And I thought, Oh, okay, now I understand - I understand suicide, in the sense that it's just relief. It's just looking for relief from the pain. But I also think we have incredible survival instincts. And for me, that immediately kicked in, but it was just..."
After a pause, the Fight Club actor added, "Yeah. Like, listen: This s**t ain't easy. And you're talking to a guy who won the lottery."
#little #relief #experienced #actor
11 days ago
Brad Pitt is opening up about an extremely dark period of his life.
The Academy Award winner, 62 — who has publicly navigated a contentious divorce from ex Angelina Jolie after their 2016 split — admitted in a Monday, August 10, Esquire interview that he had suicidal thoughts.
"I've never been suicidal except for one little period," the F1 actor said. "And in that one little period, I just thought — I just couldn't — just didn't see a way out."
"The pain was so oppressive that — I wasn't going to act on this, but I could feel — I could feel the cold steel of the bullet in my head, and it felt like relief," the father of six, who appears to have a strained relationship with his children, admitted.
"And I thought, Oh, okay, now I understand — I understand suicide, in the sense that it's just relief," Pitt said. "It's just looking for relief from the pain. But I also think we have incredible survival instincts. And for me, that immediately kicked in."
#feel
The Academy Award winner, 62 — who has publicly navigated a contentious divorce from ex Angelina Jolie after their 2016 split — admitted in a Monday, August 10, Esquire interview that he had suicidal thoughts.
"I've never been suicidal except for one little period," the F1 actor said. "And in that one little period, I just thought — I just couldn't — just didn't see a way out."
"The pain was so oppressive that — I wasn't going to act on this, but I could feel — I could feel the cold steel of the bullet in my head, and it felt like relief," the father of six, who appears to have a strained relationship with his children, admitted.
"And I thought, Oh, okay, now I understand — I understand suicide, in the sense that it's just relief," Pitt said. "It's just looking for relief from the pain. But I also think we have incredible survival instincts. And for me, that immediately kicked in."
#feel
11 days ago
Pregnant Anne Hathaway showed off her growing baby ******* p at the LA premiere of her upcoming survival thriller, "The End of Oak Street." The Oscar winner attended the star-studded event held at Warner Bros. Studios on August 9. She is all set to welcome her third baby with husband Adam Shulman.
At "The End of Oak Street" premiere, Anne Hathaway gave a peek at her baby ******* p in her custom Atelier Prabal Gurung top. The icy blue silk top featured a halter neckline, a sleeveless silhouette, and a high-low hem. The cascading train trailed behind her as she moved on the red carpet. The crimson lining contrasted with the light blue color of the top. The inverted cutout at the front created a cropped top that framed her baby ******* p.
The "Mother Mary" star paired it with baggy low-rise jeans and red and pink stiletto pumps from Aquazzura. Styled by Erin Walsh, she completed her look with sparkling drop earrings and a coiled Serpenti bracelet. She wore her hair in a high ponytail. Meanwhile, her makeup featured a clear complexion, black liner, and a classic red lip.
Hathaway announced her pregnancy with her and Shulman's third child in an Instagram video in June. They also share two sons, 10-year-old Jonathan and 7-year-old Jack. During an interview with PEOPLE on the red carpet, she opened up about how pregnancy feels different this time.
"You know, I was in my 30s with my other two, and I'm so different now …. something happened when I turned 40," she said. "I just realized that this isn't a dress rehearsal. It's all real. I'm not, like, saving it up for my future self. It's all happening right now. And so I think I'm just better at being present in the moment, living in gratitude, not taking anything for granted. So I think all of those things are coming together, and it's a real time to enjoy."
#street #premiere #Third #featured
At "The End of Oak Street" premiere, Anne Hathaway gave a peek at her baby ******* p in her custom Atelier Prabal Gurung top. The icy blue silk top featured a halter neckline, a sleeveless silhouette, and a high-low hem. The cascading train trailed behind her as she moved on the red carpet. The crimson lining contrasted with the light blue color of the top. The inverted cutout at the front created a cropped top that framed her baby ******* p.
The "Mother Mary" star paired it with baggy low-rise jeans and red and pink stiletto pumps from Aquazzura. Styled by Erin Walsh, she completed her look with sparkling drop earrings and a coiled Serpenti bracelet. She wore her hair in a high ponytail. Meanwhile, her makeup featured a clear complexion, black liner, and a classic red lip.
Hathaway announced her pregnancy with her and Shulman's third child in an Instagram video in June. They also share two sons, 10-year-old Jonathan and 7-year-old Jack. During an interview with PEOPLE on the red carpet, she opened up about how pregnancy feels different this time.
"You know, I was in my 30s with my other two, and I'm so different now …. something happened when I turned 40," she said. "I just realized that this isn't a dress rehearsal. It's all real. I'm not, like, saving it up for my future self. It's all happening right now. And so I think I'm just better at being present in the moment, living in gratitude, not taking anything for granted. So I think all of those things are coming together, and it's a real time to enjoy."
#street #premiere #Third #featured
11 days ago
Brad Pitt revealed "family stuff" once put him in a very dark place.
The Fight Club actor spent roughly eight years embroiled in legal woes with his ex-wife Angelina Jolie trying to work out the terms of their divorce. Two years after they came to a settlement, he is speaking on the emotional toll he went through during this time.
During a recent interview with Esquire, he began, "I've never been suicidal except for one little period. And in that one little period, I just thought — I just couldn't — just didn't see a way out.
"I thought, 'Oh, okay, now I understand' — I understand suicide, in the sense that it's just relief. It's just looking for relief from the pain. But I also think we have incredible survival instincts. And for me, that immediately kicked in, but it was just …," he said. "This s–t ain't easy. And you're talking to a guy who won the lottery."
When he was asked if the dark time had to deal with "kid stuff," the actor responded, "Family stuff."
#stuff #time #thought #understand
The Fight Club actor spent roughly eight years embroiled in legal woes with his ex-wife Angelina Jolie trying to work out the terms of their divorce. Two years after they came to a settlement, he is speaking on the emotional toll he went through during this time.
During a recent interview with Esquire, he began, "I've never been suicidal except for one little period. And in that one little period, I just thought — I just couldn't — just didn't see a way out.
"I thought, 'Oh, okay, now I understand' — I understand suicide, in the sense that it's just relief. It's just looking for relief from the pain. But I also think we have incredible survival instincts. And for me, that immediately kicked in, but it was just …," he said. "This s–t ain't easy. And you're talking to a guy who won the lottery."
When he was asked if the dark time had to deal with "kid stuff," the actor responded, "Family stuff."
#stuff #time #thought #understand
13 days ago
Magdeburg and Eintracht Braunschweig will start their 2026/27 season with the same opening matchday fixture from last term. The visitors took all three points that time, despite playing with ten for the entire second-half.
Both sides will aim for survival after occupying the last two spots just above the relegation zone in the 2025/26 season.
Here are how the two teams will start the game at Avent-Arena.
Magdeburg: Reimann ©; Bockhorn, Jaeckel, MacNulty, Nollenberger; Hyryläinen, Michel, Kwarteng; Iyoha, Zukowski, Atik
Braunschweig: Hoffmann ©; Aydin, Ehlers, Frenkert, Sanchez; Flick, Di Benedetto, Marie; Opoku, Urbich, Sturm
#start #here
Both sides will aim for survival after occupying the last two spots just above the relegation zone in the 2025/26 season.
Here are how the two teams will start the game at Avent-Arena.
Magdeburg: Reimann ©; Bockhorn, Jaeckel, MacNulty, Nollenberger; Hyryläinen, Michel, Kwarteng; Iyoha, Zukowski, Atik
Braunschweig: Hoffmann ©; Aydin, Ehlers, Frenkert, Sanchez; Flick, Di Benedetto, Marie; Opoku, Urbich, Sturm
#start #here
15 days ago
Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fund's outperformance, although limited exposure to managed care stocks reduced relative returns. The Fund remains positive on health care due to improving biotechnology funding, strong acquisition activity, recovering managed care margins, and growth from an aging population, chronic disease, medical innovation, and higher health care spending. In addition, please check the Fund's top five holdings to know best picks in 2026.
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Revolution Medicines, Inc. (NASDAQ:RVMD) as a new addition. Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers. On August 3, 2026, Revolution Medicines, Inc. (NASDAQ:RVMD) closed at $182.45 per share. The one-month return of Revolution Medicines, Inc. (NASDAQ:RVMD) was -4.21% and its shares gained 375.25% over the past 52 weeks. Revolution Medicines, Inc. (NASDAQ:RVMD) has a market capitalization of $38.79 billion.
Baron Health Care Fund stated the following regarding Revolution Medicines, Inc. (NASDAQ:RVMD) in its Q2 2026 investor letter:
"We added to our position in Revolution Medicines, Inc., a biotechnology company developing medicines to treat cancers driven by rat sarcoma (RAS) mutations. The company estimates there are 190,000 new cancer diagnoses each year in the U.S. that are driven by RAS mutations, including approximately 60,000 patients with non-small cell lung cancer, 75,000 patients with colorectal cancer, and 56,000 patients with pancreatic cancer. In April, the company released topline results from its RASolute 302 trial in which patients with advanced pancreatic cancer who received the company's medicine Daraxonrasib in the second line had a median overall survival of 13.2 months compared to 6.7 months for the patients who received chemotherapy. Subsequently at the annual meeting of the American Society of Clinical Oncology (ASCO), the clinical trial investigators presented the full data which confirmed the groundbreaking results. In this patient population, Daraxonrasib reduced the risk of death by 60% compared with chemotherapy. The presentation at ASCO received a standing ovation, which is rare in oncology and even rarer in pancreatic cancer. Daraxonrasib represents the first major advance in pancreatic cancer in over 30 years. Also, duri
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Revolution Medicines, Inc. (NASDAQ:RVMD) as a new addition. Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers. On August 3, 2026, Revolution Medicines, Inc. (NASDAQ:RVMD) closed at $182.45 per share. The one-month return of Revolution Medicines, Inc. (NASDAQ:RVMD) was -4.21% and its shares gained 375.25% over the past 52 weeks. Revolution Medicines, Inc. (NASDAQ:RVMD) has a market capitalization of $38.79 billion.
Baron Health Care Fund stated the following regarding Revolution Medicines, Inc. (NASDAQ:RVMD) in its Q2 2026 investor letter:
"We added to our position in Revolution Medicines, Inc., a biotechnology company developing medicines to treat cancers driven by rat sarcoma (RAS) mutations. The company estimates there are 190,000 new cancer diagnoses each year in the U.S. that are driven by RAS mutations, including approximately 60,000 patients with non-small cell lung cancer, 75,000 patients with colorectal cancer, and 56,000 patients with pancreatic cancer. In April, the company released topline results from its RASolute 302 trial in which patients with advanced pancreatic cancer who received the company's medicine Daraxonrasib in the second line had a median overall survival of 13.2 months compared to 6.7 months for the patients who received chemotherapy. Subsequently at the annual meeting of the American Society of Clinical Oncology (ASCO), the clinical trial investigators presented the full data which confirmed the groundbreaking results. In this patient population, Daraxonrasib reduced the risk of death by 60% compared with chemotherapy. The presentation at ASCO received a standing ovation, which is rare in oncology and even rarer in pancreatic cancer. Daraxonrasib represents the first major advance in pancreatic cancer in over 30 years. Also, duri
16 days ago
There was a moment last season when Roberto de Zerbi turned to his Tottenham players and asked: "Did we pass away?"
The scenes after his first game in charge - a 1-0 defeat at Sunderland - painted a grim picture.
In the dressing room, De Zerbi said players were lying on their backs, some crying following the loss at the Stadium of Light.
It was the first of seven matches De Zerbi had to keep Spurs in the Premier League.
While survival was only secured on the final day, the 47-year-old now believes he can help the club rise from the ignominy of a turbulent 2025-26 campaign.
#sunderland
The scenes after his first game in charge - a 1-0 defeat at Sunderland - painted a grim picture.
In the dressing room, De Zerbi said players were lying on their backs, some crying following the loss at the Stadium of Light.
It was the first of seven matches De Zerbi had to keep Spurs in the Premier League.
While survival was only secured on the final day, the 47-year-old now believes he can help the club rise from the ignominy of a turbulent 2025-26 campaign.
#sunderland
16 days ago
Anya Taylor-Joy says she avoids method acting, calling acting a "controlled psychosis" requiring balance and collaboration
She is best known for her roles in The Witch and The Queen's Gambit and continues to pursue ambitious projects
Taylor-Joy will next star in The Lord of the Rings: The Hunt for Gollum and Dune: Part Three
Anya Taylor-Joy has built a career playing characters who live on the edge.
From a Puritan girl haunted by supernatural forces to a chess prodigy battling addiction and a post-apocalyptic warrior fighting for survival, the actress, 30, has earned a reputation for disappearing into some of film and television's most memorable roles. But despite the emotional intensity she brings to the screen, Taylor-Joy says there's one acting technique she has never adopted: method acting.
#roles #gambit #rings
She is best known for her roles in The Witch and The Queen's Gambit and continues to pursue ambitious projects
Taylor-Joy will next star in The Lord of the Rings: The Hunt for Gollum and Dune: Part Three
Anya Taylor-Joy has built a career playing characters who live on the edge.
From a Puritan girl haunted by supernatural forces to a chess prodigy battling addiction and a post-apocalyptic warrior fighting for survival, the actress, 30, has earned a reputation for disappearing into some of film and television's most memorable roles. But despite the emotional intensity she brings to the screen, Taylor-Joy says there's one acting technique she has never adopted: method acting.
#roles #gambit #rings
17 days ago
Sometimes, fame is only the beginning of the story. In the chaotic spotlight of Hollywood, several actors have seen their meteoric rise cut short—whether by personal missteps, shifting industry tides, or life's unexpected curves.
Jeffrey Mayer / JTMPhotos, Int'l. / MEGA
Emile Hirsch achieved critical acclaim for his leading role in the major survival drama Into the Wild, but industry buzz was interrupted by off-screen controversies, per The Hollywood Reporter. Once considered one of the most promising young talents, his film appearances slowed, leaving fans and critics to wonder what might have been.
TPI/MEGA
After captivating audiences portraying twins in The Social Network, Armie Hammer seemed destined for A-list status. However, his trajectory was completely derailed by shocking allegations and public fallout, leading to roles disappearing and the industry turning cold. His accusers' claims triggered a career collapse that reportedly cost him between $14 million and $16 million in lost work, per Forbes. Despite a recent return to acting, Hammer's journey remains one of Hollywood's most public downfalls.
#public #sometimes #mayer
Jeffrey Mayer / JTMPhotos, Int'l. / MEGA
Emile Hirsch achieved critical acclaim for his leading role in the major survival drama Into the Wild, but industry buzz was interrupted by off-screen controversies, per The Hollywood Reporter. Once considered one of the most promising young talents, his film appearances slowed, leaving fans and critics to wonder what might have been.
TPI/MEGA
After captivating audiences portraying twins in The Social Network, Armie Hammer seemed destined for A-list status. However, his trajectory was completely derailed by shocking allegations and public fallout, leading to roles disappearing and the industry turning cold. His accusers' claims triggered a career collapse that reportedly cost him between $14 million and $16 million in lost work, per Forbes. Despite a recent return to acting, Hammer's journey remains one of Hollywood's most public downfalls.
#public #sometimes #mayer
18 days ago
WASHINGTON (AP) — President Donald Trump in a Saturday evening social media post claimed that Mideast allies have reached the parameters of a deal to end the Iran war and said that he would hold off on ordering new strikes in the five-month old conflict for now.
Trump added that the emerging deal "would include the Immediate, Complete, and Total OPENING OF THE HORMUZ STRAIT, and an end to Iran's nuclear threat."
"Based on this request, I have agreed, for the future benefit of the WORLD and, likewise, the survival of a successful and prosperous Iran, to cancel the attack, subject to being able to rapidly make a DEAL," Trump said.
He said that Israel has agreed to join the U.S. in the commitment to try to complete the agreement with Iran that would bring about an end to the war.
Iran did not offer any immediate public reaction to Trump's announcement.
#Iran #Trump #donald #saturday
Trump added that the emerging deal "would include the Immediate, Complete, and Total OPENING OF THE HORMUZ STRAIT, and an end to Iran's nuclear threat."
"Based on this request, I have agreed, for the future benefit of the WORLD and, likewise, the survival of a successful and prosperous Iran, to cancel the attack, subject to being able to rapidly make a DEAL," Trump said.
He said that Israel has agreed to join the U.S. in the commitment to try to complete the agreement with Iran that would bring about an end to the war.
Iran did not offer any immediate public reaction to Trump's announcement.
#Iran #Trump #donald #saturday
19 days ago
By Yasmine Ghania and Menna AlaaElDin
CAIRO, August 2 (Reuters) - President Donald Trump said late on Saturday the U.S. would hold off on a fresh attack on Iran as long as a deal could be reached quickly to halt Iran's nuclear ambitions and reopen the Strait of Hormuz.
Iran and other Middle Eastern countries asked for time to complete a deal that would lead to "the Immediate, Complete and Total" reopening of the vital strait and "an end to Iran's nuclear threat," Trump wrote on his Truth Social platform. He did not name the countries in the post, which followed a call with Crown Prince Mohammed bin Salman of Saudi Arabia, a U.S. ally.
"Based on this request, I have agreed, for the future benefit of the WORLD and, likewise, the survival of a successful and prosperous Iran, to cancel the attack, subject to being able to rapidly make a DEAL," Trump wrote.
Israel "joins me in this commitment," he said. Israel did not immediately respond on Sunday to a request for comment on the U.S. president's posts.
#deal #wrote
CAIRO, August 2 (Reuters) - President Donald Trump said late on Saturday the U.S. would hold off on a fresh attack on Iran as long as a deal could be reached quickly to halt Iran's nuclear ambitions and reopen the Strait of Hormuz.
Iran and other Middle Eastern countries asked for time to complete a deal that would lead to "the Immediate, Complete and Total" reopening of the vital strait and "an end to Iran's nuclear threat," Trump wrote on his Truth Social platform. He did not name the countries in the post, which followed a call with Crown Prince Mohammed bin Salman of Saudi Arabia, a U.S. ally.
"Based on this request, I have agreed, for the future benefit of the WORLD and, likewise, the survival of a successful and prosperous Iran, to cancel the attack, subject to being able to rapidly make a DEAL," Trump wrote.
Israel "joins me in this commitment," he said. Israel did not immediately respond on Sunday to a request for comment on the U.S. president's posts.
#deal #wrote
21 days ago
Wisconsin coach Luke Fickell admits harsh reality entering make-or-break season in Madison originally appeared on The Sporting News. Add The Sporting News as a Preferred Source by clicking here.
Wisconsin head coach Luke Fickell took the podium at Big Ten Media Days with a transparent ***** sment of his program's trajectory, boldly confronting the shortcomings of his first three seasons in Madison.
"Obviously for what we're here for, like the last two years for us have not been up to the standard. I'm not shying away from that," Fickell said, acknowledging that the struggles extended well beyond simple win-loss records into the fundamental identity, toughness, and physicality of the team.
Drawing on wisdom from his former mentor Urban Meyer, Fickell recalled the mantra "don't sleep on the game," explaining that survival in modern college football requires recognizing the rapid evolution not just of tactical schemes, but of every single facet of the sport.
Over the past eight to nine months, Fickell noted that Wisconsin undertook an exhaustive internal review of training methods, practice intensity, and player health to correct critical injuries that hampered past campaigns.
#source
Wisconsin head coach Luke Fickell took the podium at Big Ten Media Days with a transparent ***** sment of his program's trajectory, boldly confronting the shortcomings of his first three seasons in Madison.
"Obviously for what we're here for, like the last two years for us have not been up to the standard. I'm not shying away from that," Fickell said, acknowledging that the struggles extended well beyond simple win-loss records into the fundamental identity, toughness, and physicality of the team.
Drawing on wisdom from his former mentor Urban Meyer, Fickell recalled the mantra "don't sleep on the game," explaining that survival in modern college football requires recognizing the rapid evolution not just of tactical schemes, but of every single facet of the sport.
Over the past eight to nine months, Fickell noted that Wisconsin undertook an exhaustive internal review of training methods, practice intensity, and player health to correct critical injuries that hampered past campaigns.
#source
21 days ago
Lazio's hopes of signing Spanish striker Carlos Espi from Levante have faded, with Real Madrid pulling off the coup.
In recent weeks, the Biancocelesti were said to be tracking the 21-year-old centre-forward who played an instrumental role in Levante's survival last season. The young bomber netted 11 goals in 26 appearances, including decisive strikes towards the end of the campaign.
In addition to Lazio, the Spaniard had also attracted interest from the Premier League, with Hull City also on this trail. But on Thursday evening, Espi completed an out-of-the-blue transfer to Real Madrid, who identified him as the right replacement for Fulham-bound Gonzalo Garcia. The 15-time European champions confirmed the move with the following statement (via ESPN).
Real Madrid C.F. and Levante U.D. have agreed to the transfer of Carlos Espí, who will be tied to our club for the next five seasons, until June 30, 2031
Unfortunately for Lazio fans, missing out on transfer targets has become the norm rather than the exception. This summer, the management failed to finalize a deal with Bayern Munich for Jonathan Asp Jensen, who was keen to join the Italian capital side, but eventually had to accept a move to Deportivo La Coruña.
#madrid #espi #levante #spanish
In recent weeks, the Biancocelesti were said to be tracking the 21-year-old centre-forward who played an instrumental role in Levante's survival last season. The young bomber netted 11 goals in 26 appearances, including decisive strikes towards the end of the campaign.
In addition to Lazio, the Spaniard had also attracted interest from the Premier League, with Hull City also on this trail. But on Thursday evening, Espi completed an out-of-the-blue transfer to Real Madrid, who identified him as the right replacement for Fulham-bound Gonzalo Garcia. The 15-time European champions confirmed the move with the following statement (via ESPN).
Real Madrid C.F. and Levante U.D. have agreed to the transfer of Carlos Espí, who will be tied to our club for the next five seasons, until June 30, 2031
Unfortunately for Lazio fans, missing out on transfer targets has become the norm rather than the exception. This summer, the management failed to finalize a deal with Bayern Munich for Jonathan Asp Jensen, who was keen to join the Italian capital side, but eventually had to accept a move to Deportivo La Coruña.
#madrid #espi #levante #spanish
23 days ago
Jennifer Tedmori revealed the small sum she earned in residuals for her 11 episodes on Ned's Declassified
Tedmori shared her frustration over receiving checks as low as two cents, noting mailing costs exceeded their value
She now works as a lawyer but joked the total residuals might only cover a coffee at Starbucks
One child star is sharing just how much money being on a well-loved teen show still pays 20 years later.
Jennifer Tedmori posted a video on Instagram on July 24, showing around 19 envelopes she said were all residual checks she's received for her work as a child actor. Tedmori, who is now also a lawyer, was on 11 episodes of the popular Nickelodeon show Ned's Declassified School Survival Guide. As Doris Trembly, a member of the "Huge Crew" who all had a crush on Ned (Devon Werkheiser), she was a bully who would pick on other girls around the ***** ular character, mainly Moze (Lindsey Shaw).
#tedmori #residuals #checks #around
Tedmori shared her frustration over receiving checks as low as two cents, noting mailing costs exceeded their value
She now works as a lawyer but joked the total residuals might only cover a coffee at Starbucks
One child star is sharing just how much money being on a well-loved teen show still pays 20 years later.
Jennifer Tedmori posted a video on Instagram on July 24, showing around 19 envelopes she said were all residual checks she's received for her work as a child actor. Tedmori, who is now also a lawyer, was on 11 episodes of the popular Nickelodeon show Ned's Declassified School Survival Guide. As Doris Trembly, a member of the "Huge Crew" who all had a crush on Ned (Devon Werkheiser), she was a bully who would pick on other girls around the ***** ular character, mainly Moze (Lindsey Shaw).
#tedmori #residuals #checks #around
23 days ago
The company spent the past year going from survival questions to one of the market's biggest gainers, which makes its retreat from the high the more interesting story.
What Changed To Send Intel (INTC) Up More Than Fourfold?
Over the past year, Intel stock more than quadrupled, climbing about 308%, while the broader market managed nearly 18%. The move was not built on hope. By the company's own account, the conversation flipped from whether Intel could survive to how fast it can add capacity to keep up with demand. Revenue over the last twelve months reached about $57 billion and grew 7.5%, an acceleration from a three-year average near 2%. The businesses tied to AI now make up about 60% of revenue and grew 40% year over year, and management says the CPU is reclaiming ground inside AI systems, with the ratio of processors to accelerators shifting from one-in-eight toward one-in-four.
Is This Just The AI Chip Trade Lifting Everything?
Only partly. AMD rode the same wave and roughly tripled, up about 222%, but Nvidia gained only about 19% and Qualcomm about 7% over the same stretch, a fraction of that. The gains concentrated in the two biggest movers, and Intel outran even AMD. What set it apart was progress in its own factories: management says its 18A manufacturing process is yielding ahead of internal plans, and the company has pointed to multiyear deals with customers such as Google, a slot for its Xeon server chips inside Nvidia's flagship AI systems, and a headline tie-up with Elon Musk's ventures.
#year #inside
What Changed To Send Intel (INTC) Up More Than Fourfold?
Over the past year, Intel stock more than quadrupled, climbing about 308%, while the broader market managed nearly 18%. The move was not built on hope. By the company's own account, the conversation flipped from whether Intel could survive to how fast it can add capacity to keep up with demand. Revenue over the last twelve months reached about $57 billion and grew 7.5%, an acceleration from a three-year average near 2%. The businesses tied to AI now make up about 60% of revenue and grew 40% year over year, and management says the CPU is reclaiming ground inside AI systems, with the ratio of processors to accelerators shifting from one-in-eight toward one-in-four.
Is This Just The AI Chip Trade Lifting Everything?
Only partly. AMD rode the same wave and roughly tripled, up about 222%, but Nvidia gained only about 19% and Qualcomm about 7% over the same stretch, a fraction of that. The gains concentrated in the two biggest movers, and Intel outran even AMD. What set it apart was progress in its own factories: management says its 18A manufacturing process is yielding ahead of internal plans, and the company has pointed to multiyear deals with customers such as Google, a slot for its Xeon server chips inside Nvidia's flagship AI systems, and a headline tie-up with Elon Musk's ventures.
#year #inside
24 days ago
Tottenham midfielder James Maddison on Tuesday praised Roberto De Zerbi as the type of attacking coach that suited his game and said he was "excited" by what lay ahead.
Italy's De Zerbi took over from sacked interim boss Igor Tudor in March when Tottenham were winless in the Premier League in 2026.
He steered them to 17th place and survival with a tense 1-0 win over Everton on the last day of the season and has begun building a new squad with an aggressive summer of spending.
England international Maddison, who missed the majority of last season with a serious knee injury, said in Sydney he was pumped up for the next chapter.
"The manager is very clear, the goal is to be better, to play better football, to be passionate, to be proud to play for this club," said Maddison, who is reportedly set to be named Spurs' new captain.
#TOTTENHAM
Italy's De Zerbi took over from sacked interim boss Igor Tudor in March when Tottenham were winless in the Premier League in 2026.
He steered them to 17th place and survival with a tense 1-0 win over Everton on the last day of the season and has begun building a new squad with an aggressive summer of spending.
England international Maddison, who missed the majority of last season with a serious knee injury, said in Sydney he was pumped up for the next chapter.
"The manager is very clear, the goal is to be better, to play better football, to be passionate, to be proud to play for this club," said Maddison, who is reportedly set to be named Spurs' new captain.
#TOTTENHAM
